FindTrial
Sign In

Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma

Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096904
Enrollment
Unknown
Registered
2025-02-08
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-metabolic lymphoma

Interventions

Modeling group:None
Validation group:None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Histopathologically confirmed high-metabolic lymphoma; 2.Underwent 18F-FDG PET/CT imaging before, during, and after treatment; 3.Treated with a standard first-line therapeutic regimen according to lymphoma treatment guidelines and individualized patient-specific considerations; 4.Complete clinicopathological and follow-up data available;

Exclusion criteria

Exclusion criteria: 1.History of prior antitumor treatment; 2.History of other malignancies; 3.Incomplete clinical data or imaging records; 4.Presence of other concurrent malignant tumors;

Design outcomes

Primary

MeasureTime frame
receiver operating characteristic curve, ROC;Progression-Free Survival;Overall survival, OS;—

Countries

China

Contacts

Public ContactRui Guo

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

gr11734@rjh.com.cn+86 21 6431 4813

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026